CIENCIASMEDICASNEWS

domingo, 8 de noviembre de 2026

Brown fat may benefit cardiovascular, psychiatric health

https://www.nih.gov/news-events/nih-research-matters/brown-fat-may-benefit-cardiovascular-psychiatric-health Brown fat may benefit cardiovascular, psychiatric health At a Glance Researchers found brown fat activity was linked to lower odds of cardiometabolic and psychiatric diseases. A blood pressure medication boosted brown fat activity in mice, which suggests existing drugs could be repurposed to activate brown fat. 3D illustration of brown fat cell. Brown fat cells contain many mitochondria (light-brown elongated ovals), which burn energy to create heat. Love Employee / Shutterstock Brown fat burns energy to produce heat. This is different from white fat, which stores energy in the body. Brown fat reserves are found deep in the neck, thorax, armpits, and along the spine. The amount of brown fat in humans varies by factors such as age, sex, and body-mass index.

Senescence-targeting nanoparticles may enhance immunotherapy

https://www.nih.gov/news-events/nih-research-matters/senescence-targeting-nanoparticles-may-enhance-immunotherapy Senescence-targeting nanoparticles may enhance immunotherapy At a Glance Researchers developed a nanoparticle treatment in mice to eliminate certain cells that can drive tissue scarring around tumors and prevent anti-tumor therapies from working. The approach made tumors more sensitive to therapies that boost the immune response to cancer and might one day be applied to humans. The nanoparticle treatment could help immunotherapy work better on lung cancer (red) growing in areas of fibrosis (green). NIH’s National Cancer Institute / Fox Chase Cancer Center Chronic inflammation can fuel a form of scarring called fibrosis linked to cancer. Areas of fibrotic tissues often contain lots of damaged cells that no longer divide nor die off when they should. These “senescent” cells drive inflammation and fibrosis, and they inhibit nearby immune cells. As a result, tumors surrounded by fibrosis are harder to treat with immunotherapies that spur the immune system to attack cancer.

Stroke recovery tracked with wearable device

Stroke recovery tracked with wearable device At a Glance A wearable device tracked how patients recovered the ability to use their arms after a stroke. The digital tool could help personalize treatment and make it easier to test new treatments. Wrist-worn devices can provide useful information about people’s ability to use their arms during stroke rehab. voronaman / Shutterstock After a stroke, people may have trouble moving their arms. Trained specialists use clinical tests to track whether physical therapy is helping a patient recover that ability. However, those tests are time-consuming and often cannot detect small changes in how people move. They also don’t capture how people use their arms in everyday life. https://www.nih.gov/news-events/nih-research-matters/stroke-recovery-tracked-wearable-device

FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma

https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy. HNSCC is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies. Rybrevant Faspro is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma that is associated with human papillomavirus (HPV). Approval was based on trial results showing that more than double the percentage of patients responded to the drug compared to currently approved therapies. This is the first approval in 10 years of a drug for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy. “Today’s approval represents a meaningful step forward for patients with head and neck squamous cell carcinoma, a disease where treatment options have historically been limited and outcomes remain poor,” said Angelo De Claro, M.D., director of the FDA’s Oncology Center of Excellence. “This therapy offers patients and their physicians a new option with the potential to make a real difference in people’s lives.”